Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Companyâ€™s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	13.81L 11.84L 11.09L 10.13L 19.12L 13Cr 19.31L 1.31Cr 50.93L 6.64Cr 51.87L 50.74L 22Cr	P/E 2024	-2.41x	P/E 2025	-3.27x
Enterprise Value	14.61L 12.52L 11.73L 10.72L 20.23L 14Cr 20.43L 1.38Cr 53.88L 7.03Cr 54.87L 53.68L 23Cr	EV / Sales 2024	497x	EV / Sales 2025	-
Free-Float	83.91%	Yield 2024 *	-	Yield 2025	-

15/08	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
21/05	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Abpro Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
25/02	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
20/02	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
04/02	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
24/01	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
17/01	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
06/01	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
06/01	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
15/12	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
15/12	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI

15/01	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
06/01	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
15/12	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
09/12	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
04/11	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABPRO CORPORATION	-.--%	-.--%	-	-	13.81L
LONZA GROUP AG	+1.02%	+4.95%	+3.67%	+25.46%	5.17TCr
REVOLUTION MEDICINES, INC.	-0.09%	-2.14%	+492.60%	+537.84%	4.53TCr
IQVIA HOLDINGS INC.	-0.32%	+8.08%	+37.97%	+18.45%	4.27TCr
BEONE MEDICINES AG	+1.18%	+1.96%	+21.95%	+89.69%	4.28TCr
CELLTRION, INC.	-2.27%	-3.02%	+14.22%	+51.50%	3.29TCr
MEDPACE HOLDINGS, INC.	-0.96%	+4.03%	+31.55%	+136.34%	1.71TCr
ASCENDIS PHARMA A/S	+0.41%	+1.66%	-	-	1.66TCr
EUROFINS SCIENTIFIC SE	+1.12%	+6.35%	+11.00%	+32.62%	1.5TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.31%	+6.61%	+81.37%	+48.53%	1.42TCr
Average	-0.04%	+2.97%	+86.79%	+117.55%	3.09TCr
Weighted average by Cap.	+0.02%	+2.74%	+104.70%	+135.73%

	2024	2025
Net sales	2L 2L 1L 1L 3L 1.74Cr 3L 17.33L 7L 88.02L 7L 7L 2.91Cr	-
Net income	-72.32L -61.97L -58.07L -53.04L -1Cr -69Cr -1.01Cr -6.85Cr -2.67Cr -35Cr -2.72Cr -2.66Cr -115.2Cr	-28.92L -24.78L -23.22L -21.21L -40.03L -28Cr -40.42L -2.74Cr -1.07Cr -14Cr -1.09Cr -1.06Cr -46Cr
Net Debt	5L 4L 4L 4L 7L 4.56Cr 7L 45.27L 17.62L 2.3Cr 17.95L 17.56L 7.61Cr	80T 68.55T 64.23T 58.67T 1L 76.27L 1L 8L 3L 38.48L 3L 3L 1.27Cr

Abpro Corporation Share Price Nasdaq

Stocks

US0008501076

Biotechnology & Medical Research

Valuation: Abpro Corporation

Latest news : Abpro Corporation

Press Releases: Abpro Corporation

Other Biotechnology & Medical Research

Financials

Company Profile